FDA Accepts Supplemental Application for NEUPOGEN by Amgen
The FDA has accepted a supplemental application for NEUPOGEN (filgrastim) from Amgen, indicating ongoing development.
Published: July 24, 2026
Updated: July 24, 2026
Author: Humanexa Intelligence
Therapeutic area: Hematology / Neutropenia
Company: Amgen
Asset: NEUPOGEN
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Amgen
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The acceptance of the supplemental application for NEUPOGEN by Amgen is significant as it indicates ongoing development and potential enhancements in treatment options for neutropenia. This could strengthen Amgen's competitive position in the hematology market.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include the review timeline and potential approval outcomes from the FDA.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.